Openbookopenbook
Equity
Spero Therapeutics Inc(SPRO)
USD --+0.00%
Reward48Moderate
Risk57Medium-High
📊75%Data
Thin -108% profit margin · Revenue down 60% YoY
SPRO
+0.0 · +0.00%
USD · NASDAQ
Spero Therapeutics Inc | Healthcare
Earnings Deterioration
Market Cap:122.26M
ℹ️
Reward Rating
48
Moderate
Bottom 25% (model universe)
75% data coverage
ℹ️
Risk Rating
57
Medium-High
Risk Assessment
ℹ️

Educational tool only – Scores are based on historical data and financial metrics for informational purposes. This is not financial advice or a recommendation to buy or sell any security. Always conduct your own research or consult a qualified financial adviser.

ℹ️ Educational tool only · More
Limited data coverage
We don't have enough public data on SPRO to score it reliably yet — Reward, Risk, Forecasts and Dividends tabs aren't available for this stock. The price chart and basic profile are still shown.
OTC / ADR stock — scores and fundamentals use data tagged in USD by our provider. The issuer may report in a different home currency (e.g. JPY), so treat figures as directional rather than precise.
Not available for limited-coverage stocks
The overview tab requires fundamentals and price history we don't have for this stock. The price chart is the most reliable view we have — try the Chart tab.

Market Performance

Stock returned +10.0% over the past year, broadly in line with market conditions.

Analyst Target

Analyst consensus price target: $4.00.

What is Spero Therapeutics Inc?

, a clinical-stage biopharmaceutical company, focuses on identifying and developing novel treatments for multi-drug resistant (MDR) bacterial infections and rare diseases in the United States.

SPRO · Verdict

Moderate reward · elevated risk

SPRO stands out on balance sheet and valuation, but watch the cash flow signal.

Based on 88% data coverage

SPRO · Verdict

What’s working & what to watch

Strengths 2

  • Balance sheet83/100

    Current ratio 2.19

  • Valuation65/100

    Above average

Watchouts 3

  • Cash flow6/100

    -49% free-cash-flow margin

  • Profitability9/100

    -143% net margin · -95% ROE

  • Volatility35/100

    Below average

Model-based scoring. For information only — not financial advice.

What is Spero Therapeutics Inc?

, a clinical-stage biopharmaceutical company, focuses on identifying and developing novel treatments for multi-drug resistant (MDR) bacterial infections and rare diseases in the United States. The company's product candidates include Tebipenem HBr (tebipenem pivoxil hydrobromide), an oral carbapenem-class antibiotic to treat complicated urinary tract infections, including pyelonephritis for adult patients, which is in Phase 3 development; and SPR720, a novel product candidate for first-line treatment of nontuberculous mycobacterial (NTM) pulmonary disease. The company is listed on the NASDAQ in USA, operating in the Healthcare sector, with a market capitalisation of 122.26M.

Financial Highlights

Investment Breakdown

📈 Growth
Moderate growth momentum — positive trajectory without breakout acceleration.
💰 Profitability
Thin or inconsistent margins weigh on earnings quality.
⚠️ Risk
Moderate volatility with meaningful macro and earnings sensitivity.
💸 Valuation
Valuation is less clear with a negative earnings base.

OpenBook Logo Analysis

Reward: Moderate (48)

The scoring profile indicates limited reward potential at this time, with valuation and growth offering the most support. Risk indicators are elevated — volatility and macro sensitivity warrant consideration.

For informational purposes only. Not financial advice.

Company Information
SectorHealthcare
Market Cap122.26M
P/E RatioN/A
Dividend YieldN/A
52 Week High3.22
52 Week Low0.5052
Last AnnualDecember
IPO Date11/2/2017
IncorporatedUSA
Shares Outstanding56M
No. of Employees32
IndustryBiotechnology
ExchangeNASDAQ
Beta1.451
CurrencyUSD
Websitesperotherapeutics.com
openbook

Stock research for everyday UK investors. Make smarter decisions, faster.

Questions? Email us at contact@openbookanalytics.com

© 2026 Openbook Analytics Ltd · Company No. SC843579 · Registered in Scotland

256-bit encryption GDPR compliant UK data centres

Openbook Analytics Ltd (Company No. SC843579) is registered in Scotland. Registered office: Strathclyde Inspire Hub, University of Strathclyde, Graham Hills Building (Level 6), 50 Richmond Street, Glasgow, G1 1XP. Openbook Analytics is not authorised or regulated by the Financial Conduct Authority (FCA). The content on this platform is provided for general informational and educational purposes only and does not constitute financial advice, investment advice, trading advice, or any other form of advice. You should not treat any content on this platform as a recommendation to buy, sell, or hold any financial instrument. Past performance is not a reliable indicator of future results. The value of investments and the income from them can go down as well as up, and you may get back less than you invest. User-generated content, including community posts and commentary, reflects the personal opinions of individual users, is not verified for accuracy, and does not represent the views of Openbook Analytics Ltd. You should always conduct your own research or consult a qualified, FCA-regulated financial adviser before making investment decisions. Data displayed on this platform may be delayed or inaccurate and is provided "as is" without warranty. Openbook Analytics Ltd accepts no liability for any loss arising from reliance on the information provided.